Hs746T/CR
CBP60481DR-2
詢 價(jià)
留 言
產(chǎn)品描述
產(chǎn)品數(shù)據(jù)庫(kù)
| I. Background | |
| Crizotinib 作為全球首個(gè)靶向 ALK/ROS1/MET 的多激酶抑制劑，顯著改善晚期 ALK 陽(yáng) 性非小細(xì)胞肺癌（NSCLC）患者生存，但其耐藥機(jī)制主要涉及靶點(diǎn)二次突變（如 ALK L1196M 守門突變、G1202R 溶劑前沿突變直接阻礙藥物結(jié)合）、旁路信號(hào)激活 （EGFR/KIT 擴(kuò)增或 KRAS 突變驅(qū)動(dòng)替代通路）、藥代動(dòng)力學(xué)逃逸（血腦屏障穿透不足致 腦轉(zhuǎn)移進(jìn)展），以及下游信號(hào)重塑（如 STAT3/SFK 持續(xù)激活維持腫瘤生存）。 | |
| II. Introduction | |
| Host Cell: | Hs746T/CR |
| Culture Medium: | DMEM+10%FBS+500 nM Crizotinib |
| Gi50 on Hs746T： | 10.7nM |
| Gi50 on Hs746T/CR： | ＞1000nM |
| Mycoplasma Status: | Negative |
| Storage: | Liquid nitrogen |
| III. Description of Host Cell Line | |
| Organism: | Homo sapiens, human |
| Tissue: | stomach; derived from metastatic site: left leg |
| Disease: | gastric carcinoma |
| Morphology: | Epithelial |
| Growth Properties: | Adherent |
|
IV.Representative DATA |
|
|
Figure 1. CTG Proliferation Assay of Hs746T CR (Crizotinib Resistant). |
|
